Aura Biosciences said that it has dosed the first patient in a phase 1 clinical trial of its first virus-like drug conjugate (VDC) — belzupacap sarotalocan for the treatment of non-muscle invasive bladder cancer (NMIBC). According to the NASDAQ-listed clinical-stage biotech company, the early-stage multi-center, open label study is likely to take in nearly 23 […]
Aura Biosciences has secured fast track designation for belzupacap sarotalocan (AU-011) from the US Food and Drug Administration (FDA) for the treatment of non-muscle invasive bladder cancer (NMIBC). Belzupacap sarotalocan is the first virus-like drug conjugate (VDC) being developed by the American biotech company for various oncology indications. Dr. Mark De Rosch — Aura Biosciences […]
Aura Biosciences, a portfolio company of UK-based Arix Bioscience, has raised $80 million in a new funding round for developing virus-like drug conjugate (VDC) therapies for multiple oncology indications. The funding round of the US-based clinical-stage oncology company was led by Matrix Capital Management and Surveyor Capital, a Citadel company. New investors such as Rock […]